{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"67","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"To determine Progression Free Survival (PFS in symptomatic WM patients with relapsed/refractory disease. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. 40 participants were censored prior to disease progression.","dispersionType":"Full Range","groups":[{"description":"PCI-32765; ibrutinib\n\nPCI-32765: Taken orally, once daily in the morning","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"6 years","title":"Determine Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}